Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCND3 | P30281 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | FLT1 | P17948 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.30 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2022715 | 0.72 | TLR8 (0.45) | ADORA2AADORA3ADORA1ALDH1A1HPGD | |
| SCHEMBL26254230 | 0.72 | ADORA2A (0.43) | ADORA2AADORA3ADORA1ALDH1A1HPGD | |
| SCHEMBL26254231 | 0.71 | ADORA2A (0.42) | ADORA2AADORA3ADORA1ALDH1A1HPGD | |
| SCHEMBL2018893 | 0.68 | LMNA (0.42) | ADORA2AADORA3ADORA1HPGDPIM1 | |
| SCHEMBL19748950 | 0.68 | ADORA2A (0.40) | ADORA2AADORA3ADORA1ALDH1A1HPGD | |
| SCHEMBL25789219 | 0.68 | ADORA2A (0.44) | ADORA2AADORA3ADORA1ALDH1A1HPGD | |
| SCHEMBL2023069 | 0.68 | APP (0.43) | ADORA2AADORA1 | |
| SCHEMBL2021909 | 0.68 | ADORA2A (0.61) | ADORA2AADORA3ADORA1ALDH1A1HPGD | |
| SCHEMBL2022025 | 0.66 | ADORA2A (0.62) | ADORA2AADORA1ALDH1A1HSD17B10RET | |
| SCHEMBL23060023 | 0.64 | ADORA3 (0.40) | ADORA2AADORA3ADORA1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329705-B2 | Substituted triazolo-pyrazine compounds | ARQULE, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| WO-2011082267-A2 | SUBSTITUTED TRIAZOLO-PYRAZINE COMPOUNDS | ARQULE, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160215-A1 | Substituted Triazolo-Pyrazine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160215-A1 | Substituted Triazolo-Pyrazine Compounds | MKI67, TP53, THPO | ADORA2A 985/4885ADORA3 1835/4885ADORA1 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.